Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT
March 23 2022 - 12:00PM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in
cell-free, enzymatic DNA production, today announced that CEO Dr.
James A. Hayward is invited to present at the 2022 Virtual Growth
Conference presented by Maxim Group LLC and hosted by M-Vest, on
March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT. Dr. Hayward’s
presentation will be available on-demand for the duration of the
conference via the sign-up link: Sign up here to access the
presentation
During the virtual conference, investors will hear from
executives from a wide range of sectors, including Biotech, Clean
Energy, Electric Vehicles, Financial Services, Fintech & REITs,
Gaming & Entertainment, Healthcare, Healthcare IT,
Infrastructure, Shipping and Technology/Media/Telecom. The
conference will feature company presentations, fireside chats,
roundtable discussions, and live Q&A with CEOs moderated by
Maxim Research Analysts.
This conference will be live on M-Vest. To attend, sign up to
become an M-Vest member: Click Here to Reserve your seat
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary,
large-scale polymerase chain reaction ("PCR")-based manufacturing
platform that allows for the large-scale cell-free production of
specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR T therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include textiles, pharmaceuticals and
nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based
technologies, the Company has also established safeCircle™, a
high-turnkey solution for population-scale COVID-19 testing.
safeCircle is designed to look for infection within defined
populations or communities utilizing high throughput testing
methodologies that increase testing efficiencies and provide for
rapid turn-around-times.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company's common stock is listed on NASDAQ under the ticker
symbol 'APDN,' and its publicly traded warrant is listed on OTC
under the ticker symbol 'APPDW.'
Applied DNA is a member of the Russell Microcap® Index.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220323005721/en/
Investor Relations: Sanjay M. Hurry, 917-733-5573,
sanjay.hurry@adnas.com Web: www.adnas.com Twitter:
@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024